Skip to main content
SpringerLink
Log in

Antibody Inducing Polyvalent Cancer Vaccines

  • Chapter
Tumor Immunology and Cancer Vaccines

Part of the book series: Cancer Treatment and Research ((CTAR,volume 123))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

7. References

  1. Livingston, P.O. 1998. The case for melanoma vaccines that induce antibodies. In Molecular Diagnosis Prevention and Treatment of Melanoma, J.M. Kirkwood, ed. Marcel Dekker, Inc: 139–157.

    Google Scholar 

  2. Zhang, H., S. Zhang, N.K. Cheung, G. Ragupathi, and P.O. Livingston. 1998. Antibodies can eradicate cancer micrometastases. Cancer Res 58:2844–2849.

    PubMed  CAS  Google Scholar 

  3. Jones, P.C., L.L. Sze, P.Y. Liu, D.L. Morton, and R.F. Irie. 1981. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. JNCI 66:249–254.

    PubMed  CAS  Google Scholar 

  4. Livingston, P.O., G. Ritter, P. Srivastava, M. Padavan, M.J. Calves, H.F. Oettgen, and L.J. Old. 1989. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 49:7045–7050.

    PubMed  CAS  Google Scholar 

  5. Livingston, P.O., G.Y.C. Wong, S. Adluri, Y. Tao, M. Padavan, R. Parente, C. Hanlon, F. Helling, G. Ritter, H.F. Oettgen, and L.J. Old. 1994. Improved survival in AJCC stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036–1044.

    PubMed  CAS  Google Scholar 

  6. MacLean, G.D., M.A. Reddish, R.R. Koganty, and B.M. Longenecker. 1996. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother 19(1):59–68.

    CAS  Google Scholar 

  7. Singhal, A., M. Fohn, and S.I. Hakomori. 1991. Induction of a-N-acetylgalactosamine-Oserine/ threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res 51:1406–1411.

    PubMed  CAS  Google Scholar 

  8. Zhao, X.-J., and N.-K. Cheung. 1995. GD2 oligosaccharide: target for cytotoxic T lymphocytes. J Exp Med 182:67–74.

    PubMed  CAS  Google Scholar 

  9. Livingston, P.O., C. Hood, L. Krug, M.G. Kris, and G. Ragupathi. 2003. Antigen expression on Small Cell Lung Cancer (SCLC) cell lines confirms selection of a tetravalent vaccine against SCLC containing GM2, fucosyl GM1, globo H and polysialic acid. American Association for Cancer Research, Proceedings of AACR 44:4754:1090.

    Google Scholar 

  10. Livingston, P.O. 1995. Augmenting the immunogenicity of carbohydrate antigens. In Cancer Vaccines, P.O. Livingston, ed. Seminars in Cancer Biology: 357–366.

    Google Scholar 

  11. Ghossein, R., H. Scher, W. Gerald, W.K. Kelly, T. Curley, A. Amsterdam, Z.-F. Zhang, and J. Rosai. 1995. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 13:1195–1200.

    PubMed  CAS  Google Scholar 

  12. Brossart, P., U. Keilholz, M. Willhauck, C. Scheibenbogen, T. Möhler, and W. Hunstein. 1993. Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol 101(6):887–889.

    PubMed  CAS  Google Scholar 

  13. Hoon, D.S.B., Y. Wang, P.S. Dale, A.J. Conrad, P. Schmid, D. Garrison, C. Kuo, J.J. Foshag, A.J. Nizze, and D.L. Morton. 1995. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 13(8):2109–2116.

    PubMed  CAS  Google Scholar 

  14. Zhang, S., F. Helling, K.O. Lloyd, and P.O. Livingston. 1995. Increased tumor cell reactivity and complement dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides. Cancer Immunol Immunother 40:88–94.

    PubMed  CAS  Google Scholar 

  15. Lloyd, K.O. 1990. Molecular Characteristic of Tumor Antigens. Immunology Allergy Clinics of N. America.

    Google Scholar 

  16. Hakomori, S. 1984. Tumor-associated carbohydrate antigens. Annu Rev Immunol 2:103–126.

    PubMed  CAS  Google Scholar 

  17. Feizi, T. 1985. Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature 314:53–57.

    PubMed  CAS  Google Scholar 

  18. Zhang, S., C. Cordon-Cardo, H.S. Zhang, V.E. Reuter, S. Adluri, W.B. Hamilton, K.W. Lloyd, and P.O. Livingston. 1997. Selection of carbohydrate tumor antigens as targets for immune attack using immunohistochemistry. I. Focus on gangliosides. Int J Cancer 73:42–49.

    PubMed  CAS  Google Scholar 

  19. Zhang, S., H.S. Zhang, C. Cordon-Cardo, V.E. Reuter, A.K. Singhal, K.O. Lloyd, P.O. Livingston. 1997. Selection of tumor antigens as targets for immune attack using immunohistochemistry. II. Blood group-related antigens. Int J Cancer 73:50–56.

    PubMed  CAS  Google Scholar 

  20. Zhang, S., H.S. Zhang, C. Cordon-Cardo, G. Ragupathi, and P.O. Livingston. 1998. Selection of tumor antigens as targets for immune attack using immunohistochemistry: III protein antigens. Clin Cancer Res 4:2669–2676.

    PubMed  CAS  Google Scholar 

  21. Zhang, S., H.S. Zhang, V.E. Reuter, K.O. Lloyd, H. Scher, and P.O. Livingston. 1998. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 4:295–302.

    PubMed  CAS  Google Scholar 

  22. Nishinaka, Y., M.N.H. Ravindranath, and R.F. Ire. 1996. Development of a human monoclonal antibody to ganglioside GM2 with potential for cancer treatment. Cancer Res 56:5666–5671.

    PubMed  CAS  Google Scholar 

  23. Nakamura, K., M. Koike, K. Shitara, Y. Kuwana, K. Kiuragi, S. Igarashi, M. Hasegawa, and N. Hanai. 1994. Chimeric anti-ganglioside GM2 antibody with antitumor activity. Cancer Res 54:1511–1516.

    PubMed  CAS  Google Scholar 

  24. Hellström, I., H.J. Garrigues, U. Garrigues, and K.E. Hellstr öm. 1990. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Ley-related cell surface antigens. Cancer Res 50:2183–2190.

    PubMed  Google Scholar 

  25. Canevari, S., G. Fossati, A. Balsari, S. Sonnino, and M.I. Colnaghi. 1983. Immunochemical analysis of the determinant recognized by a monoclonal antibody (MBr1) which specifically binds to human mammary epithelial cells. Cancer Res 43:1301–1305.

    PubMed  CAS  Google Scholar 

  26. Mènard, S., E. Tagliabue, S. Canevari, G. Fossati, and M.I. Colnaghi. 1983. Generation of monoclonal antibodies reacting with normal and cancer cells of human breast. Cancer Res 43:1295–1300.

    PubMed  Google Scholar 

  27. Perrone, F., S. Ménard, S. Canevari, M. Claabrese, P. Boracchi, R. Bufalino, S. Testori, M. Baldini, and M.I. Colnaghi. 1993. Prognostic significance of the CaMBr1 antigen on breast carcinoma: relevance of the type of recognized glycoconjugate. Eur J Cancer 29A:2113–2117.

    PubMed  CAS  Google Scholar 

  28. Colnaghi, M.I., S. Menard, J.G. Da Dalt, R. Agresti, G. Cattoretti, S. Andreola, G. Di Fronzo, M. Del Vecchio, L. Verderio, N. Cascinelli, and F. Rilke. 1987. Amultiparametric study by monoclonal antibodies in breast cancer In Immunological Approaches to the Diagnosis and Therapy of Breast Cancer. R.L. Ceriani, ed., Plenum Publishing Corporation.

    Google Scholar 

  29. Trail, P.A., S.J. Willner, A.J. Lasch, S. Henderson, A.M. Hofstead, A.M. Casazza, R.A. Firestone, I. Hellstrom, and K.E. Hellstrom. 1993. Cure of xenografted human carcinomas by BR96-Doxorubicin immunoconjugates. Science 261:212–215.

    PubMed  CAS  Google Scholar 

  30. Burchell, J., J. Taylor-Papadimitriou, M. Boshell, S. Gendler, and T. Duhig. 1989. A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. Int J Cancer 44:691–696.

    PubMed  CAS  Google Scholar 

  31. Gendler, S.J., A.P. Spicer, E.-N. Lalani, T. Duhig, N. Peat, J. Burchell, L. Pemberton, M. Boshell, and J. Taylor-Papadimitriou. 1991. Structure and biology of a carcinoma-associated mucin, MUC1. Am Rev Respir Dis 144:S42–S47.

    PubMed  CAS  Google Scholar 

  32. Perez, L., D.F. Hayes, P. Maimonis, M. Abe, C. O’Hara, and D.W. Kufe. 1992. Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. Cancer Res 52:2563–2568.

    Google Scholar 

  33. Perey, L., D.F. Hayes, P. Maimonis, M. Abe, C. O’Hara, and D.W. Kufe. 1992. Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. Cancer Res 52:2563–2568.

    PubMed  CAS  Google Scholar 

  34. Springer, G.F. 1984. T and Tn, general carcinoma autoantigens. Science 224:1198–1206.

    PubMed  CAS  Google Scholar 

  35. Lloyd, K.O. 1987. Blood group antigens as markers for normal differentiation and malignant change in human tissues. Am J Clin Pathol 87:129–139.

    PubMed  CAS  Google Scholar 

  36. Itzkowitz, S., E.J. Bloom, W.A. Kokal, G. Modin, S-I. Hakomori, and Y.S. Kim. 1990. Sialosyl Tn: a novel mucin antigen associated with prognosis in colorectal carcinoma patients. Cancer 66:1960–1966.

    PubMed  CAS  Google Scholar 

  37. Cho, S.-H., A. Sahin, G.N. Hortobagyi, W.N. Hittelman, and K. Dhingra. 1994. Sialyl-Tn antigen expression occurs early during human mammary carcinogenesis and is associated with high nuclear grade and aneuploidy. Cancer Res 54:6302–6305.

    PubMed  CAS  Google Scholar 

  38. Thor, A., N. Obuchi, C.A. Szpak, W.W. Johnston, and J. Schlom. 1986. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 46:3118–3124.

    PubMed  CAS  Google Scholar 

  39. Longenecker, B.M., D.J. Willans, G.D. MacLean et al. 1987. Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancers. J Natl Cancer Inst 78:489–496.

    PubMed  CAS  Google Scholar 

  40. Contegiacomo, A., M. Alimandi, R. Muraro, C. Pizzi, R. Calderopoli, L. De Marchis. A. Sgambato, G. Pettinato. G. Petrella. M.R. De Filippo et al. 1994. Expression of epitopes of the tumor-associated glycoprotein 72 and clinicopathological correlations in mammary carcinomas. Eur J Cancer 30A(6):813–820.

    PubMed  CAS  Google Scholar 

  41. Zhang, S., L.A. Walberg, S. Ogata, S.H. Itzkowitz, R.R. Koganty, M. Reddish, S.S. Gandhi, B.M. Longenecker, K.O. Lloyd, and P.O. Livingston. 1995. Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Cancer Res 55:3364–3368.

    PubMed  CAS  Google Scholar 

  42. Kostakoglu, L., C.R. Divgi, T. Gilewski, M. Theodoulou, J. Schlom, and S.M. Larson. 1994. Phase II radioimmunotherapy (RIT) trail with I-131 labeled monoclonal antibody CC49 in Tag-72 expressing breast cancer. J Nucl Med (Suppl) 35:234.

    Google Scholar 

  43. Larson, S.M., J.A. Carrasquillo, D.C. Colcher et al. 1991. Estimates of radiation absorbed dose for intraperitoneally administered iodine-131 labeled B72.3 monoclonal antibody in patients with peritoneal carcinomatosis. J Nucl Med 32:1661–1667.

    PubMed  CAS  Google Scholar 

  44. MacLean, G.D., A. McEwan, A.A. Noujaim, T.R. Sykes, M.R. Suresh, Z. Catz, H.R. Hooper, and B.M. Longenecker. 1989. A novel strategy for cancer immunoscinitgrapy. Antibody Immunoconj Radiopharmaceut 2:15.

    Google Scholar 

  45. Itzkowitz, S.H., M. Yuan, C.K. Montgomery, T. Kjeldsen, H.K. Takahashi, W.K. Bigbee, and Y.S. Kim. 1989. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res 49:197–204.

    PubMed  CAS  Google Scholar 

  46. MacLean, G.D., M.A. Reddish, M.B. Bowen-Yacyshyn, S. Poppema, B.M. Longenecker. 1994. Active specific immunotherapy against adenocarcinomas. Can Invest 12(1):46–56.

    CAS  Google Scholar 

  47. Fung, P.Y.S., M. Madej, R.R. Koganty, and B.M. Longenecker. 1990. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res 50:4308–4314.

    PubMed  CAS  Google Scholar 

  48. Lackie, P.M., C. Zuber, J. Roth. 1994. Polysialic acid of the neural cell adhesion molecule (N-CAM) is widely expressed during organogenesis in mesodermal in endodermal derivatives. Differentiation 57:119–131.

    PubMed  CAS  Google Scholar 

  49. Komminoth, P., J. Roth, P.M. Lackie, D. Bitter-Suermann, P.U. Heintz. 1991. Polysialic acid of the neural cell adhesion molecule distinguishes small cell lung carcinoma from carcinoids. Am J Pathol 139:297–304.

    PubMed  CAS  Google Scholar 

  50. Hayrinen, J., H. Jennings, H.V. Raff, G. Rougon, N. Hanai, R. Gerardy-Schahn, and J. Finne. 1995. Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J Infect Dis 171:1481–90.

    PubMed  CAS  Google Scholar 

  51. Kotera, Y., J.D. Fontenot, G. Pecher, R.S. Metzgar, and O.J. Finn. 1994. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54, 2856–2860.

    PubMed  CAS  Google Scholar 

  52. Barnd, D., M. Lan, R. Metzgar, and O. Finn. 1989. Specific, MHC-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci U S A 86,7159–7163.

    PubMed  CAS  Google Scholar 

  53. Burchell, J., J. Taylor-Papadimitriou, M. Boshell, S. Gendler, and T.A. Duhig. 1989. short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. Int J Cancer 44, 691–696.

    PubMed  CAS  Google Scholar 

  54. Adluri, S., T. Gilewski, S. Zhang, V. Ramnath, G. Ragupathi, P.O. Livingston. 1999. Specificity analysis of sera from breast cancer patients vaccinated with Muc1-KLH plus QS-21. Br J Cancer 79:1806–1812.

    PubMed  CAS  Google Scholar 

  55. Hareuveni, M., C. Gautier, M.-P., Kieny, D. Wreschner, P. Chambon, and R. Lathe. 1990. Vaccination against tumor cells expression breast cancer epithelial tumor antigen. Proc Natl Acad Sci U S A 87:9498–9502.

    PubMed  CAS  Google Scholar 

  56. Zhang, S., L.A. Graeber, F. Helling. et al. 1996. Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Cancer Res 56 914 0:3315–3319.

    Google Scholar 

  57. Gottlinger, R.D., I. Funke, J.P. Johnson et al. 1986. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 38:47–53.

    PubMed  CAS  Google Scholar 

  58. Szala, S., M. Froehlich, M. Scollon et al. 1990. Molecular cloning of cDNA for the carcinoma associated antigen GA733.2. Proc Natl Acad Sci U S A 87:3542–3546.

    PubMed  CAS  Google Scholar 

  59. LoBuglio, A.F., M.N. Saleh, J. Lee et al. 1988. Phase I trial of multiple large doses ormurine monoclonal antibody CO17-1A. I. Clinical aspects. J Natl Can Inst 80:932–936.

    CAS  Google Scholar 

  60. Riethmuller, G., E. Schneider-Gadicke, G. Schlimok et al. 1994. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C. colorectal carcinoma. Lancet 343:1177–1183.

    PubMed  CAS  Google Scholar 

  61. Fair, W.R., R.S. Israeli, and W.D.W. Heston. 1997. Prostate-specific membrane antigen. The Prostate 32:140–148.

    PubMed  CAS  Google Scholar 

  62. Yin, B.W.T, and K.O. Lloyd. 2001. Molecular cloning of the CA125 ovarian cancer antigen. J Bio Chem 276(29):27371–27375.

    CAS  Google Scholar 

  63. Yin, W.T., A. Dnistrian, and K. Lloyd. 2002. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer 98:737–740.

    PubMed  CAS  Google Scholar 

  64. O’Brien, T.J., J.B. Beard, L.J. Underwood, R.A. Dennis, A.D. Santin, and L. York. 2001. The CA 125 Gene: an extracellular superstructure dominated by repeat sequences. Tumor Biol 22:348–366.

    CAS  Google Scholar 

  65. Marincola, F.M., E.M. Jaffee, D.J. Hicklin, and S. Ferrone. 2000. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181–273.

    PubMed  CAS  Google Scholar 

  66. Ferrone, S. 2002. (Guest Ed.) Tumor Escape Mechanisms. Semin Cancer Biol 12:1–86.

    Google Scholar 

  67. Krug L.M., G. Ragupathi, K.K. Ng, C. Hood, H.J. Jennings, Z. Guo, M.G. Kris, V.A. Miller, B. Pizzo, L. Tyson, V. Baez, and P.O. Livingston. 2004. Vaccination of small cell lung cancer patients with polysialic acid or n-propionylated polysialic acid conjugated to keyhole limpet hemocyanin. Clin Cancer Res 10:916–923.

    PubMed  CAS  Google Scholar 

  68. Livingston, P.O., S. Zhang, L. Walberg, G. Ragupathi, F. Helling, and M. Fleischer. 1997. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2-KLH is increased by IgG antibodies. Can Immunol Immunother 43:324–330.

    CAS  Google Scholar 

  69. Livingston, P.O., M. Jones Calves, and E.J. Natoli. Jr. 1987. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells. J Immunol 138:1524–1529.

    PubMed  CAS  Google Scholar 

  70. Helling, F., A. Zhang, A. Zhang, S. Adluri, M. Calves, R. Koganty, B.M. Longenecker, H.F. Oettgen, and P.O. Livingston. 1995. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55:2783–2788.

    PubMed  CAS  Google Scholar 

  71. Livingston, P.O., S. Adluri, F. Helling, T.-J. Yao, C.R. Kensil, M.J. Newman, and D. Marciani. 1994. Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-KLH conjugate vaccine in patients with malignant melanoma. Vaccine 12:1275–1280.

    PubMed  CAS  Google Scholar 

  72. Kim, S.-K., G. Ragupathi. S. Cappello, E. Kagan, P.O. Livingston. 2000. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine 19:530–537.

    PubMed  CAS  Google Scholar 

  73. Ritter, G., E. Boosfeld, E. Markstein, R.K. Yu, S. Ren, H.F. Oettgen, L.J. Old, and P.O. Livingston. 1990. Biochemical and serological characteristics of natural 9-O-acetyl GD3 from human melanoma and bovine buttermilk and chemically O-acetylated GD3. Cancer Res 50:1403–1410.

    PubMed  CAS  Google Scholar 

  74. Ritter, G., E. Boosfeld, M.J. Calves, H.F. Oettgen, L.J. Old, and P.O. Livingston. 1990. Antibody response after immunization with gangliosides GD3, GD3 lactones, GD3 amide and GD3 gangliosidol in the mouse. GD3 lactone I induces antibodies reactive with human melanoma. Immunobiology 182:32–43.

    PubMed  CAS  Google Scholar 

  75. Ritter, G., E. Boosfeld, R. Adluri, M. Calves, H.F. Oettgen, L.J. Old, and P.O. Livingston. 1991. Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma. Int J Cancer 48:379–385.

    PubMed  CAS  Google Scholar 

  76. Ritter, G., E. Ritter-Boosfeld, R. Adluri, M. Calves, S. Ren, R.K. Yu, H.F. Oettgen, L.J. Old, and P.O. Livingston. 1995. Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliosides in patients with malignant melanoma. Int J Cancer 62:1–5.

    Google Scholar 

  77. Helling, F., A. Shang, M. Calves, S. Zhang, S. Ren, R.K. Yu, H.F. Oettgen, and P.O. Livingston. 1994. GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res 54, 197–203.

    PubMed  CAS  Google Scholar 

  78. Kensil, C.R., U. Patel, M. Lennick, and D. Marciani. 1982. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria molina cortx. J Immunol 12:91–6.

    Google Scholar 

  79. Livingston, P.O., Jr., E.J. Natoli, M. Jones Calves, E. Stockert, H.F. Oettgen, and L.J. Old. 1987: Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci U S A 84:2911–2915.

    PubMed  CAS  Google Scholar 

  80. Kirkwood, J., J.G. Ibrahim, J.A. Sosman, V.K. Sondak, S.S. Agarwala, M.S. Ernstoff, and U. Rao. 2001. High-dose interferon Alfa-2b significantly prolongs relapse-free and overall survial compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E16954/S9512/C50901. J Clin Oncol 19(9):2370–2380.

    PubMed  CAS  Google Scholar 

  81. Dickler, M.N., G. Ragupathi, N.X, Liu, C. Musselli, D.J. Martino, V.A. Miller, M.G. Kris, F.T. Brezicka, P.O. Livingston, and S.C. Grant. 1999. Immunogenicity of the fucosyl-GM1-keyhole limpet hemocyanin (KLH) conjugate vaccine in patients with small cell lung cancer. Cancer Res 5:2773–2779.

    CAS  Google Scholar 

  82. Nores, G.A., T. Dohi, M. Taniguchi, and S.I. Hakomori. 1987. Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen. J Immunol 139:3171–3176.

    PubMed  CAS  Google Scholar 

  83. Bilodeau, M.T., T-K. Park, S. Hu, J.T. Tandolph, S.J. Danishefsky, P.O. Livingston, and S. Zhang. 1995. Total synthesis of a human breast tumor associated antigen. J Am Chem Soc 117:7840–7841.

    CAS  Google Scholar 

  84. Ragupathi, G., T.K. Park, S. Zhang, I.J. Kim, K. Graeber, S. Adluri, K.O. Lloyd, S.J. Danishefsky, and P.O. Livingston. 1997. Immunization of mice with the synthetic hexasaccharide Globo H results in antibodies against human cancer cells. Angewandte Chemie 36:125–128.

    CAS  Google Scholar 

  85. Behar, V. and S.J. Danishefsky. 1994. A highly convergent synthesis of the Lewis-Y Blood group determinant in conjugatable form. Angewandte Chem Int Ed Engl 33:1468–1470.

    Google Scholar 

  86. Ragupathi, G., S. Slovin, S. Adluri, D. Sames, I.-J. Kim, H.M. Kim, M. Spassova, W.G. Bornmann, K. Lloyd, H.I. Scher, P.O. Livingston, and S.J. Danishefsky. 1999. A fully synthetic globo H carbohydrate vaccine induces a focused humoral response in prostate cancer patients: a proof of Principle. Angewandte Chemie 38:563–566.

    CAS  Google Scholar 

  87. Kudryashov, V., H.M. Kim, G. Ragupathi, S.J. Danishefsky, P.O. Livingston, and K.O. Lloyd. 1998. Immunogenicity of synthetic conjugates of Lewisy oligosaccharide with protein in mice: towards the design of anticancer vaccines. Cancer Immunol Immunother 45:281.

    PubMed  CAS  Google Scholar 

  88. Slovin, S.F., G. Ragupathi, S. Adluri, G. Ungers, K. Terry, S. Kim, M. Spassova, W.G. Bornmann, M. Fazzari, L. Dantis, K. Olkiewicz, K.O. Lloyd, P.O. Livingston, S.J. Danishefsky, and H.I. Scher. 1999. Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc Natl Acad 96:5710–5715.

    CAS  Google Scholar 

  89. Sabbatini, P., V. Kudryashov, S. Danishefsky, P.O. Livingston, G. Ragupathi, W. Bornmann, M. Spassova, D. Spriggs, C. Aghajanian, S. Soignet, M. Peyton, C. O’Flaherty, J. Curtin, and K.O. Lloyd. 2000. Immunization of ovarian cancer patients with a synthetic LewisY-protein conjugate vaccine: clinical and serological results. Int J Cancer 87:79–85.

    PubMed  CAS  Google Scholar 

  90. Gilewski, T., G. Ragupathi, S. Bhuta, L.J. Williams, C. Musselli, X.F. Zhang, K.P. Bencsath, K.S. Panageas, J. Chin, L. Norton, A.N. Houghton, P.O. Livingston, and S.J. Danishefsky. 2001. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci U S A 98:3270–3275.

    PubMed  CAS  Google Scholar 

  91. Adluri, S., F. Helling, M.J. Calves, K.O. Lloyd, and P.O. Livingston. 1995. Immunogenicity of synthetic TF-and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol Immunother 41:185–192.

    PubMed  CAS  Google Scholar 

  92. MacLean, G.D., M.B. Bowen-Yacyshyn, J. Samuel, A. Meikle, G. Stuart, J. Nation, S. Poppema, M. Jerry, R. Koganty, T. Wong, and B.M. Longenecker. 1992. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen-Friedenreich) determinant using a synthetic carbohydrate antigen. J Immunother 11:292–305.

    PubMed  CAS  Google Scholar 

  93. Livingston, P.O., R. Koganty, B.M. Longenecker, K.O. Lloyd, and M. Calves. 1992. Studies on the immunogenicity of synthetic and natural Thomsen-Friedenreich (TF) antigens in mice: augmentation of the response by Quil A and SAF-m adjuvants and analysis of the specificity of the responses. Vaccine Res 1:99–109.

    CAS  Google Scholar 

  94. Nakada, H., M. Inoue, Y. Numata, N. Tanaka, I. Funakoshi, S. Fukui, A. Mellors, and I. Yamashina. 1993. Epitopic structure of Tn glycophorin A for an anti-Tn antibody (MLS 128). Proc Natl Acad Sci U S A 90:2495–2499.

    PubMed  CAS  Google Scholar 

  95. Kurosaka, A., H. Kitagawa, S. Fukui, Y. Numata, H. Nakada, I. Funakoshi, T. Kawasaki, T. Ogawa, H. Iijima, and I. Yamashina. 1988. A monoclonal antibody that recognizes a cluster of a disaccharide, NeuAca2-6GalNAc, in mucin-type glycoproteins. J Biol Chem 263:8724–8726.

    PubMed  CAS  Google Scholar 

  96. Springer, G.F., P.R. Desai, H. Tegtmeyer, B.D. Spencer, E.F. Scanlon. 1993. Pancarcinoma T/Tn antigen detects human carcinoma long before biopsy does and its vaccine prevents breast carcinoma recurrence. Annals N Y Acad Sci 690:355–357.

    CAS  Google Scholar 

  97. Springer, G.F. 1997. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med 75:594–602.

    PubMed  CAS  Google Scholar 

  98. MacLean, G.D., D.W. Miles, R.D. Rubens, M.A. Reddish, and B.M. Longenecker. 1996. Enhancing the effect of Theratope STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother 19(4):309–316.

    CAS  Google Scholar 

  99. MacLean, G.D., M. Reddish, R.R. Koganty, T. Wong, S. Gandhi, M. Smolenski, J. Samuel, J.M. Nabholtz, and B.M. Longenecker. 1993. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 36:215–222.

    PubMed  CAS  Google Scholar 

  100. Pon, R.A., M. Lussier, Q.L. Yang, and H.J. Jennings. 1997. N-Propionylated group B meningococcal polysaccharide mimics a Unique bactericidal capsular epitope in group B Neisseria meningitidis. J Exp Med 185(11):1929–1938.

    PubMed  CAS  Google Scholar 

  101. Gilewski, T., S. Adluri, S. Zhang, G. Ragupathi, A. Houghton, L. Norton, and P.O. Livingston. 2000. Vaccination of high risk breast cancer patients with Mucin-1 keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 6:1693–1701.

    PubMed  CAS  Google Scholar 

  102. Musselli, C., G. Ragupathi, T. Gilewski, K.S. Panageas, Y. Spinat, P.O. Livingston. 2002. Re-evaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int J Cancer 97:660–667.

    PubMed  CAS  Google Scholar 

  103. Goydos, J.S., E. Elder, T.L. Whiteside, O.J. Finn, and M.T. Lotze. 1996. A Phase I trial of a synthetic mucin peptide vaccine: induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 63:298–304.

    PubMed  CAS  Google Scholar 

  104. Reddish, M., G.D. MacLean, R.R. Kotganty et al. 1998. Anti-MUC1 class 1 restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer 76, 817–23.

    PubMed  CAS  Google Scholar 

  105. Karanikas, V., L. Hwang, J. Pearson et al. 1997. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 100, 2783–2792.

    PubMed  CAS  Google Scholar 

  106. Foon, K.A., and M. Bhattacharya-Chatterjee. 2001. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin Cancer Res 7:1154–1162.

    Google Scholar 

  107. Murphy, G., B. Tjoa, H. Ragde, G. Kenny, and A. Boynton. 1996. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific membrane antigen. Prostate 29:371–380.

    PubMed  CAS  Google Scholar 

  108. Tjoa, B.A., S.J. Simmons, A. Elgamal et al. 1999. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 40:125–129.

    PubMed  CAS  Google Scholar 

  109. Colten, H.R. and F.S. Rosen. 1992. Complement deficiencies. Ann Rev Immunol 10:809–834.

    CAS  Google Scholar 

  110. Ragupathi, G., F. Koide, N. Sathyan, E. Kagan, M. Spassova, W. Bornmann, P. Gregor, C.A. Reis, H. Clausen, S.J. Danishefsky, and P.O. Livingston. 2003. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers, Cancer Immunol Immunother 52:608–616.

    PubMed  CAS  Google Scholar 

  111. Ragupathi, G., M. Meyers, S. Adluri, L. Howard, R.K. Yu, G. Ritter, and P.O. Livingston. 2000. Phase I trial with GD3-lactone-KLH conjugate and immunological adjuvant QS-21 vaccine with malignant melanoma. Int J Cancer 85:659–666.

    PubMed  CAS  Google Scholar 

  112. Liu, N.X., G. Ragupathi, S. Cappello, C. Musselli, and P.O. Livingston. 2000. Antibodies against cancer cell surface glycolipids and proteins, but not mucins mediate complement-dependent cytotoxicity. AACR Proc 41:5582.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Tumor Vaccinology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York City, New York

    Govind Ragupathi PhD., John Gathuru PhD. & Philip Livingston M.D.

Authors
  1. Govind Ragupathi PhD.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Gathuru PhD.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philip Livingston M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Vaccine Branch, National Cancer Institute, Bethesda Naval Hospital Bethesda, MD, USA

    Samir N. Khleif

  2. King Hussein Cancer Center, Amman, Jordan

    Samir N. Khleif

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Kluwer Academic Publishers

About this chapter

Cite this chapter

Ragupathi, G., Gathuru, J., Livingston, P. (2005). Antibody Inducing Polyvalent Cancer Vaccines. In: Khleif, S.N. (eds) Tumor Immunology and Cancer Vaccines. Cancer Treatment and Research, vol 123. Springer, Boston, MA. https://doi.org/10.1007/0-387-27545-2_7

Download citation

  • DOI: https://doi.org/10.1007/0-387-27545-2_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4020-8119-4

  • Online ISBN: 978-0-387-27545-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation